1.Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; ...
与 HER2 阴性的肿瘤患者相比,HER2低表达的乳腺癌患者激素受体(hormone receptor,HR)阳性比率更高,患者的无进展生存期(progress-free survival,PFS)和总生存期(overall survival,OS)也更长[3]。此外,HER2 低表达状态是动态的,重复连续...
[4] Sara M. Tolaney, ,et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) ...
[4]Sara A. Hurvitz, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. 2022 SABCS abstract GS2-02. [5]Hamilton E, Hurvitz S, Im S, et al. Trastuzumab...
[3]de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, Goncalves A, Bertucci F. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181–188. ...
16.Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, et al. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One. 2020;15(11):e0241775. ...
1. Leon-Ferre RA, et al. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negativeand HER2-Positive Breast Cancer Ann Surg Oncol, 2021.28(4): p.2111-2119. 2. de Nonneville A,et al. Pathological complete response rate and disease-free survival afterneoadjuvant chemotherapy in patients ...
HER2 status was scored as negative (immunohistochemistry 0) or low (immunohistochemistry 1 + or 2 + without amplification). We associated HER2 status with several clinicopathologic characteristics, gene-expression data and survival, stratified for estrogen receptor (ER) status. Overall, breast...
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the A... Evidence-based definitions of 'poor-prognosis' or 'aggressive' advanced breast cancer are lacking. We developed a prognostic factor index usi...
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in...